Abstract: The disclosure relates to a light-emitting device including a first electrode, a second electrode facing the first electrode, and an interlayer disposed between the first electrode and the second electrode and including an emission layer. The interlayer includes a first compound represented by Formula 1 of the specification, a second compound represented by Formula 2 of the specification, and a third compound, which is a blue phosphorescent compound. The disclosure also relates to an electronic apparatus including the light-emitting device.

Abstract: The present disclosure provides a composition. The composition includes a silane functionalized polyolefin; a flame retardant; and a hindered amine light stabilizer (HALS) having a Mw greater than 5,000 Dalton. The present disclosure also provides a coated conductor. The coated conductor includes a conductor and a coating on the conductor, the coating including a composition. The coating composition includes a silane functionalized polyolefin; a flame retardant; and a hindered amine light stabilizer (HALS) having a Mw greater than 5,000 Dalton.

Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.

Abstract: The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.

Abstract: Disclosed are platinum or palladium complexes featuring tetradentate ligands with at least one side that has an NN binding motif are disclosed. The disclosed organometallic compounds have a structure of where M is Pt or Pd. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: The present invention relates to carbazole derivatives, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices comprising same.

Abstract: A compound for an organic optoelectronic device, an organic optoelectronic device, and a display device, the compound being represented by Chemical Formula 1:

Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.

Abstract: Compounds of general formula (I), isomers, salts, or hydrates thereof. Herbicide compositions including: at least one compound of general formula (I); at least one solvent and/or at least one diluent; and, optionally, at least one agronomically acceptable excipient.

Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.

Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Abstract: The present disclosure relates to an organic compound having the following structure, and an organic light emitting diode (OLED) and an organic light emitting device including the organic compound. The organic compound is a bipolar compound having a p-type moiety and an n-type moiety and has high energy level and proper energy bandgap for an emissive layer of the OLED. As the organic compound is applied into the emissive layer, the OLED can maximize its luminous properties as holes and electrons are recombined uniformly over the whole area in an EML.

Abstract: Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.

Abstract: The present specification relates to an organic light emitting device including: an anode; a cathode disposed to face the anode; and a light emitting layer disposed between the anode and the cathode, in which the light emitting layer includes: a host including a P-type host and an N-type host, which produce an exciplex; and a phosphorescent dopant, and the host including the P-type host and the N-type host, which produce an exciplex, emits a photoluminescence light with a longer wavelength than a wavelength of each of the P-type host and the N-type host.

Abstract: A modified collagen fiber preparation method and application are provided. The modified collagen fiber is prepared by modifying a collagen fiber with a plant tannin; and a method of the preparation includes: mixing the plant tannin with the collagen fiber in a liquid environment with a pH of 5 to 8 to allow a reaction, and washing and drying a product. In the present disclosure, a plant tannin rich in phenolic hydroxyl can be combined with a collagen fiber in various ways such as multi-point hydrogen bonding and hydrophobic bonding, such that the plant tannin structure is introduced into a natural multi-layer micro/nano-structure of the collagen fiber; and due to a large number of phenolic hydroxyl structures in the plant tannin, the collagen fiber introduced with the plant tannin structure shows improved compatibility with a waterborne resin, and can produce strong hydrogen bonding with polar groups in the waterborne resin.

Abstract: A compound for an organic optoelectronic device, an organic optoelectronic device including the same, and a display device, the compound being represented by Chemical Formula 1:

Abstract: A composition which is useful for producing a light emitting device having excellent external quantum efficiency contains two or more compounds represented by the formula (C-1) and a phosphorescent compound, in which at least one of the compounds represented by the formula (C-1) is a compound in which RC is a group represented by the formula (C?-1). Ring R1C and Ring R2C represent an aromatic hydrocarbon ring or an aromatic hetero ring. RC represents an oxygen atom, a sulfur atom or a group represented by the formula (C?-1). Ring R3C and Ring R4C represent an aromatic hydrocarbon ring or an aromatic hetero ring. RC? represents a carbon atom, a silicon atom, a germanium atom, a tin atom or a lead atom.

Abstract: A condensed cyclic compound represented by Formula 1 and an organic light-emitting device including the same: wherein, in Formulae 1, Y11 is a group represented by Formulae 2-1 to 2-3 and Y12 is a group represented by Formulae 3-1 to 3-5, 4-1, or 4-2 as described herein.

Abstract: Disclosed is an organic compound that includes a fused hetero aromatic moiety of a spiro structure as an electron donor and a triazine moiety as an electron acceptor that is linked to the electron donor via an arylene linker substituted with at least one electron withdrawing group, an organic light emitting diode and an organic light emitting device each of which applies the organic compound into at least one emitting unit. The organic compound enables the organic light emitting diode to increase its luminous efficiency and to improve its color purity.

Abstract: A leuco composition comprises at least one reactive leuco compound, which reactive leuco compound comprises a leuco moiety and at least one reactive moiety covalently bound to the leuco moiety. A laundry care composition comprises a laundry care ingredient and a leuco composition. A method of treating a textile comprises the steps of (i) treating a textile with an aqueous solution containing a leuco composition, (ii) optionally, rinsing the textile, and (iii) drying the textile.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having low driving voltage and/or high luminous efficiency can be provided. At the same time or selectively, an organic electroluminescent device having excellent lifespan characteristic and/or formable of a thin film of excellent quality can be provided.

Abstract: Provided are phosphoramidate nucleoside compounds of Formula (I), or pharmaceutically acceptable salts or esters or solvates thereof, useful in the treatment of cancer, viral infections and other diseases: Also provided is a process for the synthesis of compounds of Formula (I) where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.

Abstract: The present invention relates to heterocyclic compounds and to electronic devices, especially organic electroluminescent devices, comprising these compounds.

Abstract: The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.

Abstract: Provided are an organic electroluminescence device having high current efficiency and a long lifetime, and a biscarbazole derivative for realizing the device. The biscarbazole derivative has a specific substituent. The organic EL device has a plurality of organic thin-film layers including a light emitting layer between a cathode and an anode, and at least one layer of the organic thin-film layers contains the biscarbazole derivative.

Abstract: An organic electroluminescent device includes: a substrate; a first electrode on the substrate; a second electrode on the first electrode; and a plurality of lamination layers between the first and second electrodes; wherein at least one of the plurality of lamination layers includes a carbazole compound represented by Formula 1: The carbazole compound may improve the emission efficiency of the organic electroluminescent device.

Abstract: A material for an organic electroluminescent device and an organic electroluminescent device including the same, according to one or more embodiments of the present disclosure, include an amine derivative represented by Formula 1. When the amine derivative represented by Formula 1 is included in the emission layer, the emission efficiency of the organic electroluminescent device may be improved.

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract: An ultra low loss dielectric thermosetting resin composition has at least one cyanate ester component (A) and at least one reactive intermediate component (B) that is capable of copolymerization with said component (A). The invention is a cyanate ester resin of the form: Tn-[W-(Z)f/(H)1?f-W]n?1-[W-(Z)f/(H)1?f-(OCN)f/(R)1?f]n+2, wherein T is a 1,3,5-substituted-triazine moiety (C3N3); W is a linking atom between triazine and either component A or component B; Z is component (A); H is component (B); OCN is a cyanate ester end group; R is a reactive end group of component B; n is an integer greater than or equal to 1; and f is a weight or mole fraction of component A. The composition exhibits excellent dielectric properties and yields a high performance laminate for use in high layer count, multilayer printed circuit board (PCB), prepregs, resin coated copper (RCC), film adhesives, high frequency radomes, radio frequency (RF) laminates and various composites.

Abstract: A ultra low loss dielectric thermosetting resin composition has at least one cyanate ester component (A) and at least one reactive intermediate component (B) that is capable of copolymerization with said component (A). The invention is a cyanate ester resin of the form: Tn-[W-(Z)f/(H)1?f-W]n?1-[W-(Z)f/(H)1?f-(OCN)f/(R)1?f]n+2, wherein T is a 1,3,5-substituted-triazine moiety (C3N3); W is a linking atom between triazine and either component A or component B; Z is component (A); H is component (B); OCN is a cyanate ester end group; R is a reactive end group of component B; n is an integer greater than or equal to 1; and f is a weight or mole fraction of component A. The composition exhibits excellent dielectric properties and yields a high performance laminate for use in high layer count, multilayer printed circuit board (PCB), prepregs, resin coated copper (RCC), film adhesives, high frequency radomes, radio frequency (RF) laminates and various composites.

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract: A ultra low loss dielectric thermosetting resin composition has at least one cyanate ester component (A) and at least one reactive intermediate component (B) that is capable of copolymerization with said component (A). The invention is a cyanate ester resin of the form: Tn-[W-(Z)f/(H)1?f-W]n?1-[W-(Z)f/(H)1?f-(OCN)f/(R)1?f]n+2, wherein T is a 1,3,5-substituted-triazine moiety (C3N3); W is a linking atom between triazine and either component A or component B; Z is component (A); H is component (B); OCN is a cyanate ester end group; R is a reactive end group of component B; n is an integer greater than or equal to 1; and f is a weight or mole fraction of component A. The composition exhibits excellent dielectric properties and yields a high performance laminate for use in high layer count, multilayer printed circuit board (PCB), prepregs, resin coated copper (RCC), film adhesives, high frequency radomes, radio frequency (RF) laminates and various composites.

Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: Provided are a compound represented by the following Chemical Formula 1 for an organic optoelectronic device, an organic light emitting diode including the same, and a display device including the organic light emitting diode. The structure of Chemical Formula 1 is described in the specification. The compound for the organic photoelectric device provides an organic light emitting diode having excellent life-span characteristics due to excellent electrochemical and thermal stability and high luminous efficiency at a low driving voltage.

Abstract: The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention has excellent luminous efficiency, power efficiency, and lifespan characteristic. Using the compounds of the present invention, it is possible to manufacture an OLED device with a long operating lifespan. In addition, the compounds can improve the power efficiency of the device to reduce overall power consumption.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

Abstract: A compound for an organic optoelectronic device, an organic light emitting diode, and a display device, the compound including sequentially combined substituents represented by the following Chemical Formulae 1 to 3:

Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: A condensed cyclic compound represented by Formula 1: wherein in Formula 1, Groups X1 to X3, L11, L12, R11, and R12, and variables a11, a12, b11, b12, c11, and c12 are described in the specification.

Abstract: A compound represented by Formula 1 or 2, and an organic light-emitting device including the same are disclosed. Formulae 1 and 2 are defined as in the specification.

Abstract: An organic compound represented by Formula 1 is disclosed. An organic light-emitting device including the organic compound is also disclosed.

Abstract: The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.

Abstract: A compound for an organic photoelectric device, the compound being represented by the following Chemical Formula (“CF”) 1:

Abstract: A compound for an organic optoelectric device, an organic optoelectric device including the same, and a display device including the organic optoelectric device, the compound including a combination of a moiety represented by the following Chemical Formula I and a moiety represented by the following Chemical Formula II:

Abstract: The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.

Abstract: Provided is an organic electroluminescent device (organic EL device), which has improved luminous efficiency, has sufficient driving stability, and has a simple construction. The organic EL device of the present invention is an organic electroluminescent device, including a light-emitting layer and a hole-transporting layer between an anode and a cathode laminated on a substrate, in which the light-emitting layer contains a phosphorescent light-emitting dopant and an indolocarbazole compound that serves as a host material, or alternatively, the hole-transporting layer contains an indolocarbazole compound. The indolocarbazole compound is represented by the following formula (1). In the formula: A1's each represent an aromatic hydrocarbon group or an aromatic heterocyclic group, provided that at least one of A1's has a fused ring structure; and R1's each represent a hydrogen atom, an alkyl group, an alkoxy group, or an acyl group.

Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.